New Research Highlights Improvements in Quality of Life and Caregiver Experience for Home Hemodialysis Patients Using Tablo
Outset Medical (Nasdaq: OM) presented new research at Kidney Week 2024 demonstrating significant benefits of their Tablo Hemodialysis System for home hemodialysis patients and caregivers. Two key findings were highlighted: First, patients reported improvements in depression and faster recovery from treatments, with high recommendation scores (NPS of 9.2-9.3). Second, caregivers showed strong confidence in supporting treatments, with 98% feeling confident and 100% satisfied with their role, resulting in high recommendation scores (NPS of 8.9). Additionally, a study in Kidney Medicine provided consensus recommendations for catheter use in home hemodialysis, suggesting individualized approaches for vascular access.
Outset Medical (Nasdaq: OM) ha presentato nuove ricerche alla Kidney Week 2024, dimostrando i significativi benefici del loro Tablo Hemodialysis System per i pazienti in emodialisi a casa e i loro caregivers. Due risultati chiave sono stati evidenziati: innanzitutto, i pazienti hanno riportato miglioramenti nella depressione e un recupero più rapido dopo i trattamenti, con punteggi di raccomandazione elevati (NPS tra 9.2 e 9.3). In secondo luogo, i caregivers hanno mostrato forte fiducia nel supportare i trattamenti, con il 98% che si sente sicuro e il 100% soddisfatto del proprio ruolo, risultando in punteggi di raccomandazione elevati (NPS di 8.9). Inoltre, uno studio pubblicato su Kidney Medicine ha fornito raccomandazioni consensuali per l'uso dei cateteri in emodialisi domiciliare, suggerendo approcci personalizzati per l'accesso vascolare.
Outset Medical (Nasdaq: OM) presentó nueva investigación en la Kidney Week 2024 que demuestra los importantes beneficios de su Tablo Hemodialysis System para pacientes de hemodiálisis en el hogar y sus cuidadores. Se destacaron dos hallazgos clave: en primer lugar, los pacientes informaron mejoras en la depresión y una recuperación más rápida de los tratamientos, con altos puntajes de recomendación (NPS de 9.2-9.3). En segundo lugar, los cuidadores mostraron una fuerte confianza en apoyar los tratamientos, con un 98% sintiéndose seguros y un 100% satisfechos con su papel, lo que resultó en altos puntajes de recomendación (NPS de 8.9). Además, un estudio en Kidney Medicine proporcionó recomendaciones consensuadas para el uso de catéteres en hemodiálisis en el hogar, sugiriendo enfoques individualizados para el acceso vascular.
Outset Medical (Nasdaq: OM)은 Kidney Week 2024에서 자택 혈액 투석 환자와 보호자를 위한 Tablo Hemodialysis System의 중요한 이점을 보여주는 새로운 연구 결과를 발표했습니다. 두 가지 주요 발견이 강조되었습니다: 첫째, 환자들은 우울증 호전과 치료 후 빠른 회복을 보고했으며, 높은 추천 점수(NPS 9.2-9.3)를 기록했습니다. 둘째, 보호자들은 치료를 지원하는 데 강한 자신감을 보였으며, 98%가 자신감을 느끼고 100%가 자신의 역할에 만족한다고 응답하여 높은 추천 점수(NPS 8.9)를 얻었습니다. 또한, Kidney Medicine에 발표된 연구는 자택 혈액 투석에서 카테터 사용에 대한 합의된 권장 사항을 제공했으며, 혈관 접근을 위한 개별화된 접근 방안을 제안했습니다.
Outset Medical (Nasdaq: OM) a présenté de nouvelles recherches lors de la Kidney Week 2024, démontrant les avantages significatifs de leur Tablo Hemodialysis System pour les patients en hémodialyse à domicile et les aidants. Deux résultats clés ont été mis en avant : tout d'abord, les patients ont signalé des améliorations de la dépression et une récupération plus rapide après les traitements, avec des scores de recommandation élevés (NPS de 9,2 à 9,3). Ensuite, les aidants ont montré une forte confiance dans le soutien aux traitements, 98% se sentant confiants et 100% satisfaits de leur rôle, ce qui a conduit à des scores de recommandation élevés (NPS de 8,9). De plus, une étude publiée dans Kidney Medicine a fourni des recommandations consensuelles pour l'utilisation des cathéters en hémodialyse à domicile, suggérant des approches individualisées pour l'accès vasculaire.
Outset Medical (Nasdaq: OM) präsentierte auf der Kidney Week 2024 neue Forschungen, die die signifikanten Vorteile ihres Tablo Hemodialysis System für Patienten der häuslichen Hämodialyse und deren Pflegepersonen demonstrieren. Zwei wesentliche Ergebnisse wurden hervorgehoben: Erstens berichteten die Patienten von Verbesserungen bei Depressionen und einer schnelleren Genesung nach den Behandlungen, mit hohen Empfehlungsbewertungen (NPS von 9,2 bis 9,3). Zweitens zeigten die Pflegepersonen ein starkes Vertrauen in die Unterstützung der Behandlungen, wobei 98% sich sicher fühlten und 100% mit ihrer Rolle zufrieden waren, was zu hohen Empfehlungsbewertungen (NPS von 8,9) führte. Darüber hinaus lieferte eine Studie in Kidney Medicine konsensbasierte Empfehlungen für die Verwendung von Kathetern bei der häuslichen Hämodialyse und schlug individualisierte Ansätze für den vaskulären Zugang vor.
- High patient satisfaction demonstrated by NPS scores of 9.2-9.3 out of 10
- Strong caregiver satisfaction with 98% confidence rate and 100% satisfaction rate
- Documented improvements in patient depression and recovery time
- Caregiver recommendation score (NPS) maintained at 8.9 over 12 months
- None.
Insights
The research findings demonstrate significant positive outcomes for Outset Medical's Tablo Hemodialysis System, particularly in addressing mental health and quality of life aspects of home hemodialysis (HHD). Key highlights include:
- Patient depression improvement and faster recovery from dialysis treatments over 12 months
- Exceptional Net Promoter Scores of 9.2 and 9.3 at 6 and 12 months respectively
- Care partner confidence rates of
98% and satisfaction rates of100% - Strong care partner NPS of 8.9 consistently at both 6 and 12 months
The consensus recommendations regarding catheter use could expand the addressable market for home hemodialysis by providing more flexible vascular access options. This research validates Tablo's effectiveness in improving patient outcomes and caregiver experience, potentially driving broader adoption in the growing home dialysis market.
Outset Medical features patient experience poster
presentations at Kidney Week 2024
Consensus recommendations for use of catheters in home
hemodialysis patients published in Kidney Medicine
SAN JOSE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset″), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced two new research posters that demonstrate significant quality of life and mental health benefits for patients and their caregivers using its Tablo® Hemodialysis System for home hemodialysis (HHD).
“As physicians, we understand that a critical component of effective treatment includes not just providing physical relief, but also addressing the very real and challenging emotional aspects of managing end-stage kidney disease,” said Michael Aragon, MD, Chief Medical Officer of Outset Medical. “Our poster presentations at Kidney Week 2024 provide real-world evidence that Tablo is effective at helping both those in need of dialysis and their caregivers take back their life and build confidence in their treatment. Positive mental health and quality of life are essential factors in making this a reality.”
The following posters will be presented at Kidney Week 2024:
Improvement in Depression and Quality of Life in HHD Patients: Patients with end-stage renal disease (ESRD) commonly report depressive symptoms (e.g., feeling hopeless, suicidal thoughts), significantly impacting quality-of-life and feelings of self-worth (e.g., feeling like a failure, letting your family down). These symptoms can impact a patient’s overall sense of well-being as well as treatment recovery time. Patients on Tablo participating in the HOME Registry Study reported improvement in depression and faster recovery from dialysis treatments, over 12 months of observation. Importantly, at both 6 and 12 months, patients using Tablo at home reported that they were extremely likely to recommend home hemodialysis with Tablo to other patients. The mean Net Promoter Score (NPS) for likelihood of recommending HHD with Tablo to other ESRD patients on a 10-point scale from 1 “not likely” to 10 “extremely likely” was 9.2 at month 6 and 9.3 at month 12.
Caregiver Support for Tablo Home Hemodialysis: Care partners surveyed in this study reported confidence in their training and their ability to care for their loved one with little impact on their own quality of life. Care partner responses after completing training show
The posters will be showcased at the American Society of Nephrology’s (ASN) Kidney Week 2024 in San Diego, which runs October 23-27, 2024. More than 13,000 leading kidney health professionals gather at the annual conference to share the latest advances in kidney science and collaborate on kidney care innovation. Attendees are invited to meet the presenting authors in the Outset booth (#713) during the ASN meeting to ask questions or learn more about Tablo. The full posters can be viewed on the Outset Medical clinical evidence page following the conference.
New consensus recommendations published for catheter use in home hemodialysis
A recent study published in the October 14 issue of Kidney Medicine titled “Vascular Access for Home Hemodialysis: A Perspective on Tunneled Central Venous Catheters at Home” explores the issue of vascular access for HHD. While tunneled hemodialysis (HD) central venous catheters (CVC) have been used for decades, physicians still hesitate to send patients home without a mature, functional arteriovenous access.
The study convened an expert panel of clinicians to review available literature and provide consensus recommendations regarding the use of CVC for HHD. The research recommended that an end-stage kidney disease life plan should be created via shared decision-making for modality choices, with the corresponding dialysis access individualized for the patient, and for whom a CVC may represent the most appropriate vascular access to provide HHD.
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Indications for Use
The Tablo® Hemodialysis System and TabloCart™ is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute or chronic care facility. Treatments must be administered under physician’s prescription and observed by a trained individual who is considered competent in the use of the device. The Tablo Hemodialysis System is also indicated for use in the home. Treatment types available include Intermittent Hemodialysis (IHD), Sustained Low Efficiency Dialysis (SLED/ SLEDD), Prolonged Intermittent Renal Replacement Therapy (PIRRT), and Isolated Ultrafiltration.
This device is not indicated for continuous renal replacement therapy (CRRT) and is cleared for use for up to 24 hours. The dialysate generated by this device is not sterile and should not be used for intravenous (IV) infusion.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements regarding Outset’s beliefs, projections and expectations concerning, among other things, the potential impact of the research results discussed in this press release. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause actual results and other events to differ materially from those expressed or implied in such statements. These risks and uncertainties include risks described in the Risk Factors section of Outset’s public filings with the U.S. Securities and Exchange Commission, including its latest annual and quarterly reports. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Outset disclaims any obligation to update these forward-looking statements.
For more information:
Investor Contact
Jim Mazzola
jmazzola@outsetmedical.com
Media Contact
Jennifer Sipple
media@outsetmedical.com
2246-v1
FAQ
What were the patient satisfaction scores for Tablo home hemodialysis system (OM) in 2024?
How satisfied were caregivers with the Tablo system (OM) according to the 2024 research?
What mental health benefits did Outset Medical's Tablo system (OM) show in the 2024 study?
